BioCentury

8:00 AM GMT, Feb 27, 2012
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/24 cls
Gentium S.p.A. (NASDAQ:GENT) ThinkEquity Mani Mohindru Upgrade Buy (from sell) 1% $8.68
Mohindru also raised his target to $11 from $4 after Gentium submitted responses to Day 120 questions from EMA's CHMP related to the review of defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in

Read the full 743 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.